The Benefits of Tight Glycemic Control in Type 2 Diabetes Mellitus

Clinical Cornerstone

Volumn 8, Issue SUPPL. 7, 2007, Pages

  LeRoith, Derek ^a   Rayfield, Elliot J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOCANNABINOID; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BLOOD GLUCOSE MONITORING; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DEPRESSION; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PATIENT MONITORING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; SELF MONITORING; SIDE EFFECT; TREATMENT CONTRAINDICATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 37349057104     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(07)80018-4     Document Type: Article

References (43)

1. Haffner S., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 (2006) S4-S42 (Suppl 1)
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes' Care 26 (2003) 917-932
4. Knopp R., d'Emden M., Smilde J., and Pocock S. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
5. Selvin E., Coresh J., Golden S., et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: The Atherosclerosis Risk in Communities Study. Arch Intern Med 165 (2005) 1910-1916
6. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med 124 (1996) 127-130
7. Lehto S., Ronnemaa T., Haffner S., et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46 (1997) 1354-1359
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
9. Mudaliar S. Intense management of diabetes mellitus: Role of glucose control and antiplatelet agents. J Clin Pharmacol 44 (2004) 414-422
10. Burchfiel C., Tracy R., Chyou P., and Strong J. Cardiovascular risk factors and hyalinization of renal arterioles at autopsy. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol 17 (1997) 760-768
11. Chiasson J., Josse R., Gomis R., et al., for the STOPNIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPNIDDM trial. JAMA 290 (2003) 486-494
12. Delorme S., and Chiasson J. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 5 (2005) 184-189
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
14. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
15. Schellhase K., Koepsell T., and Weiss N. Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med 37 (2005) 139-140
16. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
17. Lebovitz H., Austin M., Blonde L., et al., for the ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: Consensus conference recommendations. Endocr Pract 12 Suppl1 (2006) 6-12
18. LeRoith D., and Smith D. Monitoring glycemic control: The cornerstone of diabetes care. Clin Ther 27 (2005) 1489-1499
19. Dandona R., and Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 90 (2002) 27G-33G (5A)
20. Ratner R., Goldberg R., Haffner S., et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28 (2005) 888-894
21. Donner T. Tight control of hyperglycemia in type 2 diabetes mellitus. Insulin 1 (2006) 166-172
22. Rayfield E., and Valentine M. Chapter 2: Pathophysiology and clinical management of diabetes and prediabetes. In: Mechanick J., and Brett E. (Eds). Nutritional Strategies for the Diabetic and Pre-diabetic Patient (2006), CRC Press Taylor & Francis Group, Boca Raton, Fla 15-44
23. Giannarelli R., Aragona M., Coppelli A., and Del Prato S. Reducing insulin resistance with metformin: The evidence today. Diabetes Metab 29 (2003) 6S28-6S35
24. Avenell A., Broom J., Brown T., et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technology Assessment 8 (2004) 36-47. http://www.hta.ac.uk/project/1187.asp Available at: Accessed May 31, 2007
25. Van de Laar F., Lucassen P., Akkermans R., et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) CD003639
26. Wagner H., Degerblad M., Thorell A., et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 29 (2006) 1471-1477
27. Sharma A., and Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92 (2007) 386-395
28. Dormandy J., Charbonnel B., Eckland D., et al., for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
29. Murata G., Duckworth W., Hoffman R., et al. Hypoglycemia in type 2 diabetes: A critical review. Biomed Pharmacother 58 (2004) 551-559
30. Scheen A., Finer N., Hollander P., et al., for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 368 (2006) 1660-1672
31. Wing R., Marcus M., Epstein L., and Salata R. Type II diabetic subjects lose less weight than their overweight non-diabetic spouses. Diabetes Care 10 (1987) 563-566
32. Guare J., Wing R., and Grant A. Comparison of obese NIDDM and nondiabetic women: Short- and long-term weight loss. Obes Res 3 (1995) 329-335
33. Drucker D., and Nauck M. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
34. Byetta® (exenatide injection) Prescribing Information. Amylin Pharmaceuticals, Inc; San Diego, Calif. Literature revised February 2007. Available at:. Accessed February 12, 2007.
35. http://pi.lilly.com/us/byetta-pi.pdf
36. Januvia™ (sitagliptin tablets) Prescribing Information. Merck & Co, Inc; Whitehouse Station, NJ. 2006. Available at:. Accessed February 12, 2007.
37. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
38. Tangalos E., Cota D., and Fujioka K. Complex cardiometabolic risk factors: Impact, assessment, and emerging therapies. J Am Med Dir Assoc 7 (2006) 1-10 (Suppl 7)
39. Kyrou I., Valsamakis G., and Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann NY Acad Sci 1083 (2006) 270-305
40. Engeli S., Bohnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
41. Van Gaal L., Rissanen A., Scheen A., et al., for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
42. Pi-Sunyer F., Aronne L., Heshmati H., et al., for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295 (2006) 761-775
43. Després JR Golay A., Sjostrom L., and for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134